Vigilant Biosciences, Inc. Employee Directory

Biotechnology ResearchTexas, United States11-50 Employees

Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of cancer. The BeVigilant™ OraFusion System aids  clinicians with identifying patients at risk for oral cancers. It is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. 
 
The BeVigilant™ OraFusion System, the first and only technology that measures tumor-initiating and stem cell associated biomarkers – markers clinically validated to be associated with oral cancer – was developed to aid clinicians in the early detection of oral cancer.

The point-of-care BeVigilant™ OraFusion System uses a simple collection method that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant™ OraFusion System is CE Marked and available in select markets outside of the United States. The BeVigilant™ OraFusion System is not available for sale in the U.S. 


Leadership:

Bill Brodie, Chief Executive Officer
Robert T. Hamilton, CPA, Chief Financial Officer
Dragan Nebrigic, Ph.D., Chief Operating Officer
Ben Beckham, Chief Commercial Officer
Michael Donovan, M.D. Ph.D., Chief Clinical Officer

Sign up for free to view info

Company overview Email format